HomeNews

Photocure ASA: Annual accounts 2017

Published: 16 April 2018Financial Investment & Stock

Oslo, 16 April 2018: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2017.

The annual accounts and annual report for the financial year 2017 are enclosed with this notification and made available on the company's website, www.photocure.com.  

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.no

About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company focusing on urology. Based on its unique proprietary Photocure Technology® platform, Photocure is committed to developing and commercializing highly selective and minimally invasive solutions to improve health outcomes for patients worldwide. The company is listed on the Oslo Stock Exchange (OSE: PHO). More information about Photocure is available at www.photocure.com, www.hexvix.com, www.cysview.com.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

News and events

NEWS POST
test
Oslo, Norway
16 May 2023
NEWS POST
test
Oslo, Norway
8 February 2023
PRESS-RELEASE
New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement
Oslo, Norway
3 January 2023
NEWS POST
Bladder Cancer: New Meta-analysis
Oslo, Norway
15 December 2022
NEWS POST
Photocure Partner Asieris announces First Patient treated in Hexvix Real-world Evidence study in Hainan, China
Oslo, Norway
12 December 2022
NEWS POST
Photocure to participate in the NALSC and DNB Healthcare Conferences in December
Oslo, Norway
5 December 2022
PRESS-RELEASE
New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting
Oslo, Norway
5 December 2022
OSE Notice
Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting
Oslo, Norway
7 November 2022
PRESS-RELEASE
Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China
Oslo, Norway
4 November 2022
OSE Notice
Photocure ASA: Results for the third quarter of 2022
Oslo, Norway
2 November 2022
OSE Notice
Photocure ASA: Invitation to presentation of third quarter 2022 financial results
Oslo, Norway
25 October 2022
PRESS-RELEASE
Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC
Oslo, Norway
4 October 2022
PRESS-RELEASE
Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.
Oslo, Norway
28 September 2022
PRESS-RELEASE
New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia
Oslo, Norway
20 September 2022
PRESS-RELEASE
Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance
Oslo, Norway
15 September 2022
PRESS-RELEASE
Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology
Oslo, Norway
8 September 2022
GLOBAL HEADQUARTERS

Photocure ASA
Hoffsveien 4
0275 Oslo
Norway

E-mail: info@photocure.no
NORTH AMERICA

Photocure INC
202 Carnegie Center
Suite 101, Princeton,
NJ 08540, USA

E-mail: info@photocure.com
EUROPE

Photocure GmbH
Marc-Chagall-Str. 2
40477 Düsseldorf
Germany

E-mail: kontakt@photocure.com
Follow us
Privacy PolicyTerms of use
© Photocure 2024
Key InformationProviding an update on the XYZ incident

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do